Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA).

Noa Bregman^1,2,3, Nuno Pedrosa de Barros⁴, Talya Nathan⁵, Mori Hay Levy⁵, Diana Sima⁴, Simon Van Eyndhoven⁴, Aya Bar-David⁵, Orna Aizenstein^6,7, Dana Niry⁷, Lilian Atlan⁷, Anan Abu Awad⁵, Elissa Ash^5,8,6, Nurit Omer^5,8, Tamara Shiner^5,8,6

¹Cognitive Neurology Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv, 6423906, Israel. noabr@tlvmc.gov.il.

²Department of Neurology and Neurosurgery, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. noabr@tlvmc.gov.il.

³Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel. noabr@tlvmc.gov.il.

⁴icometrix, Leuven, Belgium.

⁵Cognitive Neurology Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv, 6423906, Israel.

⁶Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.

⁷Department of Radiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

⁸Department of Neurology and Neurosurgery, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.

PubMed DOI

Abstract

INTRODUCTION: Lecanemab, a monoclonal antibody targeting amyloid beta, has demonstrated meaningful clinical benefits in early Alzheimer's disease (AD), yet real-world data is needed to optimize patient selection and enhance safety monitoring, particularly with respect to amyloid-related imaging abnormalities (ARIA). Integration of quantitative and AI-derived MRI biomarkers may improve risk stratif…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.